Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118905 · ClinicalTrials.gov registry record · Phase 4
Preserving Geriatric Muscle With an Osteoporosis Medication
A Phase 4 study of Osteoporosis, sponsored by Susan L. Greenspan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT06118905: Recruiting Phase 4 study of Osteoporosis, sponsored by Susan L. Greenspan.
NCT06118905 is a Phase 4 study of Osteoporosis that is actively recruiting participants, run by Susan L. Greenspan. The registered enrollment target is 155 participants, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06118905, a Phase 4 study of Osteoporosis, is actively recruiting participants, sponsored by Susan L. Greenspan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
Primary Outcome
The primary muscle strength outcome measure will be the peak muscle force generated by the dominant leg (same side as dominant hand) knee extensor muscles in the sitting position with the knee at 60 degrees of flexion.
Conditions Studied
Interventions
- DRUG Denosumab 60 MG/ML
- DRUG Zoledronic Acid 5Mg/Bag 100Ml Infusion
Study Locations (1)
Pennsylvania
- St. Barnabas Woodlands - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 4 |
What NCT06118905 shows while recruiting
NCT06118905 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Denosumab 60 MG/ML is the first listed.
NCT06118905 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06118905 about?
NCT06118905 is a clinical study titled "Preserving Geriatric Muscle With an Osteoporosis Medication". Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
What is the current status of trial NCT06118905?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 155 participants. The study started on 2024-02-08. Estimated completion is 2029-03-31.
What conditions does trial NCT06118905 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT06118905?
The interventions under investigation include: Denosumab 60 MG/ML (DRUG), Zoledronic Acid 5Mg/Bag 100Ml Infusion (DRUG).
Who is sponsoring clinical trial NCT06118905?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118905 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06118905's enrollment target sits among peer trials
155 34th of 84 higher than 51 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI